Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Macrogenics (MGNX) Operating Expenses (2016 - 2025)

Historic Operating Expenses for Macrogenics (MGNX) over the last 14 years, with Q3 2025 value amounting to $54.2 million.

  • Macrogenics' Operating Expenses fell 409.43% to $54.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $241.2 million, marking a year-over-year decrease of 290.43%. This contributed to the annual value of $260.5 million for FY2024, which is 1477.89% up from last year.
  • Latest data reveals that Macrogenics reported Operating Expenses of $54.2 million as of Q3 2025, which was down 409.43% from $59.0 million recorded in Q2 2025.
  • Macrogenics' 5-year Operating Expenses high stood at $77.7 million for Q1 2022, and its period low was $45.9 million during Q3 2023.
  • For the 5-year period, Macrogenics' Operating Expenses averaged around $63.7 million, with its median value being $62.9 million (2023).
  • Its Operating Expenses has fluctuated over the past 5 years, first soared by 3193.89% in 2021, then crashed by 3117.46% in 2023.
  • Over the past 5 years, Macrogenics' Operating Expenses (Quarter) stood at $72.4 million in 2021, then decreased by 15.56% to $61.1 million in 2022, then fell by 1.71% to $60.1 million in 2023, then rose by 20.17% to $72.2 million in 2024, then dropped by 24.92% to $54.2 million in 2025.
  • Its last three reported values are $54.2 million in Q3 2025, $59.0 million for Q2 2025, and $55.8 million during Q1 2025.